Surgery News

SAN FRANCISCO — Final 5-year data from the EXCEL trial demonstrate similar rates of death, stroke or MI with PCI or CABG for treatment of patients with left main CAD, according to late-breaking data presented at TCT 2019.

SAN FRANCISCO — At 5 years, transcatheter aortic valve replacement with the Sapien XT device was similar to surgical AVR for death and disabling stroke in patients with severe aortic stenosis at intermediate surgical risk, according to new data from the PARTNER 2A trial.

SAN FRANCISCO — In a CT substudy of the PARTNER 3 trial of low surgical risk patients who underwent transcatheter or surgical aortic valve replacement, hypoattenuated leaflet thrombosis and reduced leaflet motion were not associated with death, MI and stroke, according to data presented at TCT 2019.

Whether you attended the European Society of Cardiology Congress in person or followed from afar, Cardiology Today and Healio have you covered.

The FDA has accepted an investigational new drug application to evaluate the efficacy of Elysium Health’s cellular health supplement in preventing acute kidney injury in patients who undergo cardiac surgery.

The Keck School of Medicine of the University of Southern California received a $4.5 million grant from the NIH and NHLBI to fund efforts in recruiting underrepresented groups to clinical trial, namely the predominantly Hispanic population of Los Angeles, according to a press release.

Healio and Cardiology Today compiled a list of the most-viewed cardiology posts in August. This month, our readers were interested in barriers for women with heart disease, a science advisory on omega-3 fatty acids, healthy plant-based diets, diversity in cardiology and much more.

PARIS — Metabolic surgery for patients with obesity and type 2 diabetes was linked to lower incidence of major adverse CV events compared with nonsurgical methods of metabolic management, according to a presentation at the European Society of Cardiology Congress.

The second annual SCAI SHOCK meeting, organized by the Society for Cardiovascular Angiography and Interventions, aims to offer information to help clinicians better diagnose and treat cardiogenic shock, and to promote the establishment of institutional and regional shock teams for better care, according to its program co-chair.

PARIS — New data from the SWEDEHEART registry presented at the European Society of Cardiology Congress show that use of statins, antiplatelet therapies and renin-angiotensin-aldosterone system inhibitors yields reduced risk for mortality after CABG.